Novel treatments emerge for rheumatoid arthritis and other chronic conditions, while regulatory approaches and drug tolerability remain key concerns in modern medicine.

Tetrandrine, a compound derived from Chinese herbs, demonstrates efficacy in treating moderate to severe rheumatoid arthritis in patients already on methotrexate, though placebo response rates remain notably high in trials.

Zemprocitinib, a next-generation JAK1 inhibitor, successfully targets refractory rheumatoid arthritis that has failed to respond to at least one biologic disease-modifying antirheumatic drug, according to phase 3 clinical trial results.

Petrelintide, an amylin analog, achieves significant body weight reduction with tolerability profiles comparable to placebo, potentially addressing gastrointestinal side effects associated with GLP-1 medications.

Low-dose naltrexone fails to provide clinically meaningful benefits for fibromyalgia patients compared to placebo, challenging its use as a treatment option for this chronic pain condition.

New research suggests corticosteroids may not be a major driver of gestational diabetes risk, though clinical impacts vary significantly depending on individual patient characteristics.

NICE has recommended seladelpar for primary biliary cholangitis treatment, offering dual benefits of targeting disease progression and alleviating severe itching symptoms.

Analysis reveals that MHRA regulations on isotretinoin, imposed due to psychiatric safety concerns, have cost the NHS up to £1.4 million in wasted clinical time across 12,000 hours.

Eye care practice scope expansion is under consideration in multiple states to address specialist shortages, raising questions about whether nonphysicians should perform in-office surgical procedures.